#South Korea #Seoul #Neurophet AQUA #AI Imaging #Dementia Diagnosis

Neurophet's Breakthrough in Dementia Imaging

The recent publication of clinical validation results for Neurophet AQUA in the Annals of the Academy of Medicine Singapore marks a significant advancement in the field of AI-assisted diagnostics for brain disorders. Conducted at the Dementia Research Centre of Nanyang Technological University in Singapore, this clinical study aimed to evaluate the effectiveness of Neurophet's innovative technology in analyzing brain images of individuals affected by cognitive decline.

Study Overview

The study ran from April 2022 to July 2023 and included a diverse cohort of 90 participants. This group comprised 30 healthy volunteers, 40 individuals diagnosed with mild cognitive impairment (MCI), and 20 with dementia. The crux of the research involved assessing white matter hyperintensity (WMH) and gray matter volume to evaluate neurological health.

Key Findings

The results were impressive—Neurophet AQUA exhibited a strong correlation (ρ=0.66, p<0.0001) with expert medical evaluations regarding WMH. Furthermore, when compared with other automated imaging tools like LST and CAT12, Neurophet AQUA's metrics were similarly robust, boasting correlation coefficients ranging from ρ=0.84 to 0.85 (p<0.0001).

The analysis conducted through Neurophet AQUA revealed substantial atrophy in key brain regions associated with dementia—the hippocampus and posterior cingulate cortex. This capability allows for a clearer understanding of the progression from being cognitively normal to showing signs of MCI and eventually dementia.

One of the most striking capabilities of Neurophet AQUA is its speed; gray matter segmentation was achieved in just five minutes, a stark contrast to traditional methods which can take hours. The dual analysis of both gray matter and WMH could be completed in under 20 minutes, greatly enhancing clinical efficiency.

Clinical Implications

The implications of these findings are vast. Neurophet AQUA stands to revolutionize the way clinicians diagnose dementia and formulate treatment plans, allowing for quicker and more precise assessments. This makes it an invaluable tool in the real-world clinical setting, vital for timely patient care.

Donghyeon Kim, the Co-CEO of Neurophet, emphasized the importance of this study, stating, "This study demonstrated the clinical validity of Neurophet AQUA in a patient cohort from Singapore. It marks an important milestone proving that Neurophet's technology can be trusted in global clinical practice."

Future Directions

In addition to these achievements, Neurophet is actively pursuing partnerships to expand its influence in the healthcare sector. The company recently signed a supply agreement with the National University of Singapore and Singapore General Hospital for its PET image quantification software, Neurophet SCALE PET. This collaborative approach aims to integrate various imaging techniques to enhance the diagnostic process further.

About Neurophet

Founded in 2016, Neurophet specializes in creating AI-driven solutions designed to support the diagnosis and treatment of brain disorders. With a focus on understanding and improving brain health, the company is at the forefront of combining cutting-edge technology with clinical necessity. Its product lineup includes various innovations, like the Neurophet AQUA for MRI analysis, the Neurophet SCALE PET for PET imaging, and specialized software for conditions such as Alzheimer's Disease and Multiple Sclerosis.

Neurophet is committed to advancing the field of neuro-diagnostics, targeting important issues in brain health with its pioneering technology, which serves as a beacon of hope for patients and healthcare providers alike.